A Multicenter, Randomized, Controlled, Open-label, Rater-blinded Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of ALXN1840 Versus Standard of Care in Pediatric Participants With Wilson Disease

This study is being conducted to evaluate the efficacy, safety, pharmacokinetics (PK), and pharmacodynamics of ALXN1840 versus standard of care in pediatric participants with Wilson disease (WD).

Start Date13 Sep 2021

Sponsor / Collaborator

Alexion Pharmaceuticals, Inc.

EUCTR2020-005832-31-DK / Unknown statusPhase 2

Efficacy of ALXN1840 on human hepatic copper uptake quantified with 64CuCl2 PET/CT-scan. - ALXN1840-HV-Cu Absorption

Start Date13 Apr 2021

Sponsor / Collaborator

Alexion Pharmaceuticals, Inc.

EUCTR2021-000102-25-DK / Unknown statusPhase 2IIT

Efficacy of ALXN1840 on human biliary copper excretion quantified with 64CuCl2 PET/MR-scan - ALXN1840-WD-Cu Excretion

Start Date09 Apr 2021

Sponsor / Collaborator

Århus Universitetshospital

100 Clinical Results associated with Bis-choline tetrathiomolybdate

100 Translational Medicine associated with Bis-choline tetrathiomolybdate

100 Patents (Medical) associated with Bis-choline tetrathiomolybdate

137

Literatures (Medical) associated with Bis-choline tetrathiomolybdate

01 Oct 2024·JOURNAL OF ETHNOPHARMACOLOGY

Qiju Dihuang Pill protects the lens epithelial cells via alleviating cuproptosis in diabetic cataract

Article

Author: Kuang, Xinqi ; Gao, Yichen ; Tian, Fang ; Yang, Jun ; Mao, Han

ETHNOPHARMACOLOGICAL RELEVANCE:

Qiju Dihuang Pill (QDP) is a traditional Chinese medicine prescription for the treatment of eye diseases. Novel literature reports that copper-induced cell death, called as cuproptosis, is a copper-dependent and differs distinctly from other types of cell death.

AIM OF THE STUDY:

The present study aims to investigate whether QDP could protect lens epithelial cells via alleviating copper-induced death in diabetic cataract.

MATERIALS AND METHODS:

The different concentration of QDP medicated serum was administrated on high glucose (HG)-induced human lens epithelial cells (HLECs). The copper concentration was tested using Elabscience Copper Assay kit. The proliferation was detected using CCK-8 and EdU assays. The molecular binding was identified using RIP-PCR and luciferase reporter assay.

RESULTS:

Results indicated that HG culture condition triggered the copper concentration and repressed the proliferation of HLECs. Then, the elesclomol-Cu (Es-Cu) administration up-regulated the copper concentration and inhibited the proliferation, and cuproptosis inhibitor tetrathiomolybdate (TTM) could specifically reverse the consequence. QDP treatment reduced the copper concentration and cuproptosis-related genes (SLC31A1, FDX1). MeRIP-Seq and RIP-PCR confirmed that QDP reduced the stability of SLC31A1 mRNA through m⁶A modified site, and copper actually synergized the molecular binding efficiency. Rescue assay verified the role of QDP and SLC31A1 on HLECs' cuproptosis characteristic.

CONCLUSION:

This research identified the protective role of QDP on HG-induced HLECs in DC through decreasing m⁶A/SLC31A1-mediated cuproptosis in DC. This finding provides novel insights into mechanisms for QDP and sheds light on the multifaceted role of traditional prescription on DC.

01 Sep 2024·FREE RADICAL BIOLOGY AND MEDICINE

Superoxide signal orchestrates tetrathiomolybdate-induced longevity via ARGK-1 in Caenorhabditis elegans

Article

Author: Liu, Li ; Zhou, Yiming ; Wei, Fang ; Zhang, Mengting ; Li, Guolin ; Duan, Zhigui ; Lu, Siyu

PURPOSE:

While reactive oxygen species (ROS) have been identified as key redox signaling agents contributing to aging process, which and how specific oxidants trigger healthy longevity remain unclear. This paper aimed to explore the precise role and signaling mechanism of superoxide (O₂^•-) in health and longevity.

METHODS:

A tool for precise regulation of O₂^•- levels in vivo was developed based on the inhibition of superoxide dismutase 1 (SOD1) by tetrathiomolybdate (TM) in Caenorhabditis elegans (C. elegans). Then, we examined the effects of TM on lifespan, reproduction, lipofuscin accumulation, mobility, and stress resistance. Finally, the signaling mechanism for longevity induced by TM-O₂^•- was screened by transcriptome analysis and tested in sod-1 and argk-1 RNAi strains, sod-2, sod-3, and daf-16 mutants.

RESULTS:

TM promoted longevity in C. elegans with a concomitant extension of healthy lifespan as indicated by increasing fertility and mobility and reducing lipofuscin accumulation, as well as enhanced resistance to different abiotic stresses. Mechanically, TM could precisely regulate O₂^•- levels in nematodes via modulating SOD1 activity. An O₂^•- scavenger Mn(III)TBAP abolished TM-induced lifespan extension, while an O₂^•- generator paraquat at low concentration mimicked the life prolongation effects. The longevity in TM-treated worms was abolished by sod-1 RNAi but was not affected in sod-2 or sod-3 mutants. Further transcriptome analysis revealed arginine kinase ARGK-1 and its downstream insulin/insulin-like growth factor 1 signaling (IIS) as potential effectors for TM-O₂^•‾-induced longevity, and argk-1 RNAi or daf-16 mutant nullified the longevity.

CONCLUSIONS:

These findings indicate that it is feasible to precisely control specific oxidant in vivo and O₂^•- orchestrates TM-induced health and longevity in C. elegans via ARGK-1-IIS axis.

01 Apr 2024·Journal of hepatology

Effects of tetrathiomolybdate on copper metabolism in healthy volunteers and in patients with Wilson disease

Article

Author: Munk, Ditte Emilie ; Sandahl, Thomas Damgaard ; Kirk, Frederik Teicher ; Swenson, Eugene Scott ; Quicquaro, Adam Michael ; Vendelbo, Mikkel Holm ; Schilsky, Michael L ; Ott, Peter ; Larsen, Agnete

BACKGROUND & AIMS:

In Wilson disease (WD), copper accumulates in the liver and brain causing disease. Bis-choline tetrathiomolybdate (TTM) is a potent copper chelator that may be associated with a lower risk of inducing paradoxical neurological worsening than conventional therapy for neurologic WD. To better understand the mode of action of TTM, we investigated its effects on copper absorption and biliary excretion.

METHODS:

In a double-blind randomized setting, hepatic ⁶⁴Cu activity was examined after orally administered ⁶⁴Cu by PET/CT in 16 healthy volunteers before and after seven days of TTM treatment (15 mg/d) or placebo. Oral ⁶⁴Cu was administered one hour after the final TTM dose. Changes in hepatic ⁶⁴Cu activity reflected changes in intestinal ⁶⁴Cu uptake. Additionally, in four patients with WD, the distribution of ⁶⁴Cu in venous blood, liver, gallbladder, kidney, and brain was followed after i.v. ⁶⁴Cu dosing for up to 68 hours before and after seven days of TTM (15 mg/day), using PET/MRI. Increased gallbladder ⁶⁴Cu activity was taken as evidence of increased biliary ⁶⁴Cu excretion.

RESULTS:

In healthy volunteers, TTM reduced intestinal ⁶⁴Cu uptake by 82% 15 hours after the oral ⁶⁴Cu dose. In patients with WD, gallbladder ⁶⁴Cu activity was negligible before and after TTM, while TTM effectively retained ⁶⁴Cu in the blood, significantly reduced hepatic ⁶⁴Cu activity at all time-points and significantly reduced cerebral ⁶⁴Cu activity two hours after the intravenous ⁶⁴Cu dose.

CONCLUSIONS:

While we did not show an increase in biliary excretion of ⁶⁴Cu following TTM administration, we demonstrated that TTM effectively inhibited most intestinal ⁶⁴Cu uptake and retained ⁶⁴Cu in the blood stream, limiting the exposure of organs like the liver and brain to ⁶⁴Cu.

IMPACT AND IMPLICATIONS:

Bis-choline tetrathiomolybdate (TTM) is an investigational copper chelator being developed for the treatment of Wilson disease. In animal models of Wilson disease, TTM has been shown to facilitate biliary copper excretion. In the present human study, TTM surprisingly did not facilitate biliary copper excretion but instead reduced intestinal copper uptake to a clinically significant degree. Our study builds on our understanding of human copper metabolism and the mechanism of action of TTM.

News (Medical) associated with Bis-choline tetrathiomolybdate

20 Dec 2024

·ir.monopartx.com

Monopar Therapeutics Inc. Announces Pricing of $40 Million Public Offering of Common Stock and Concurrent Private Placement of Pre-Funded Warrants

WILMETTE, Ill., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) (“Monopar” or the “Company”), a clinical-stage biotechnology company focused on developing innovative treatments for patients with unmet medical needs, today announced the pricing of an underwritten registered offering of 798,655 shares of its common stock at an offering price of $23.79 per share. In addition to the shares sold in the registered offering, Monopar announced the concurrent pricing of a private placement of pre-funded warrants to purchase 882,761 shares of common stock at a purchase price of $23.789 per pre-funded warrant, which represents the per share offering price for the common stock less the $0.001 per share exercise price for each pre-funded warrant. The gross proceeds to Monopar from the registered offering and private placement, before deducting the underwriting discounts and commissions and estimated offering expenses, are expected to be $40 million. The offering is expected to close on or about December 23, 2024, subject to customary closing conditions. Monopar intends to use the net proceeds from the offering for general corporate purposes, which may include research and development expenditures, clinical trial expenditures, manufacture and supply of product, and working capital. RA Capital Management, Janus Henderson Investors, Adage Capital Partners LP and ADAR1 Capital Management participated in the offering. Piper Sandler & Co. is acting as the sole book-running manager for the offering. The securities in the registered offering are being offered and sold pursuant to a "shelf" registration statement on Form S-3 (File No. 333-268935), including a base prospectus, filed with the U.S. Securities and Exchange Commission (the “SEC”) on December 21, 2022, and declared effective on January 4, 2023. A prospectus supplement and accompanying prospectus describing the terms of the registered offering will be filed with the SEC and will be available on its website at www.sec.gov. Copies of the prospectus supplement and the accompanying prospectus relating to the registered offering, when available, may also be obtained by contacting Piper Sandler & Co. by mail at Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, by telephone at (800) 747-3924 or by email at prospectus@psc.com. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About Monopar Therapeutics Inc. Monopar Therapeutics is a clinical-stage biotechnology company with late-stage ALXN-1840 for Wilson disease, and radiopharma programs including Phase 1-stage MNPR-101-Zr for imaging advanced cancers, and Phase 1a-stage MNPR-101-Lu and late preclinical-stage MNPR-101-Ac225 for the treatment of advanced cancers. For more information, visit: www.monopartx.com. Forward-Looking Statements Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Examples of these forward-looking statements include statements concerning: statements regarding the completion of the offering, the satisfaction of customary closing conditions related to the offering and the anticipated use of proceeds therefrom. The forward-looking statements involve risks and uncertainties including, but not limited to: our ability to raise sufficient funds in order for us to support continued clinical, regulatory and commercial development of our programs and to make contractual future milestone payments, as well as our ability to further raise additional funds in the future to support any existing or future product candidate programs through completion of clinical trials, the approval processes and, if applicable, commercialization; uncertainties related to the regulatory discussions we intend to initiate related to ALXN-1840 and the outcome thereof; the rate of market acceptance and competitiveness in terms of pricing, efficacy and safety, of any products for which we receive marketing approval, and our ability to competitively market any such products as compared to larger pharmaceutical firms; and the significant general risks and uncertainties surrounding the research, development, regulatory approval, and commercialization of imaging agents and therapeutics. Actual results may differ materially from those expressed or implied by such forward-looking statements. Risks are described more fully in Monopar's filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Monopar undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. Any forward-looking statements contained in this press release represent Monopar’s views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. CONTACT:   Monopar Therapeutics Inc. Investor Relations Karthik Radhakrishnan   Chief Financial Officer   karthik@monopartx.com Released December 20, 2024

Phase 1

05 Dec 2024

·www.globenewswire.com

Monopar Announces First Patient Dosed with its Novel Therapeutic Radiopharmaceutical MNPR-101-Lu

WILMETTE, Ill., Dec. 05, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biotechnology company focused on developing innovative treatments for patients with unmet medical needs, today announced the first patient ever dosed with MNPR-101-Lu. This novel therapeutic radiopharmaceutical combines MNPR-101, Monopar’s antibody that selectively targets the urokinase plasminogen activator receptor (uPAR), with the therapeutic radioisotope lutetium-177. uPAR is involved in tumor growth and metastasis, and is found in some of the most aggressive, deadly cancers, including pancreatic, ovarian, triple negative breast, and colorectal cancers. The MNPR-101-Lu intravenous infusion was well-tolerated with no serious adverse reactions reported. This patient, dosed under a compassionate use protocol in the US, has metastatic pancreatic cancer, and prior to dosing, the cancer was imaged using MNPR-101-Zr (a zirconium-89 imaging radioisotope conjugated to MNPR-101) with a PET/CT scanner and showed uPAR expression.“As a result of encouraging biodistribution and dosimetry clinical data we recently reported (link) with our radiodiagnostic, MNPR-101-Zr, we have been eagerly looking forward to initiating treatment of patients with MNPR-101-Lu, hopeful it may provide an important therapeutic benefit to a group of cancer patients very much in need,” said Chandler Robinson, MD, Monopar’s Chief Executive Officer.“We are thrilled to have dosed this patient with MNPR-101-Lu, and believe this may be the world’s first dosing of a patient with a uPAR-targeted therapeutic radiopharmaceutical,” said Andrew Cittadine, Monopar’s Chief Operating Officer. Monopar is actively enrolling participants in two Phase 1 clinical studies in Australia, evaluating MNPR-101-Zr for imaging and MNPR-101-Lu for treatment of advanced solid tumors. Further information about the MNPR-101-Lu Phase 1a trial is available at www.ClinicalTrials.gov under study identifier NCT06617169. Further information about the MNPR-101-Zr Phase 1 imaging and dosimetry clinical trial is available at www.ClinicalTrials.gov under study identifier NCT06337084. About Monopar Therapeutics Inc.Monopar Therapeutics is a clinical-stage biotechnology company with ALXN-1840 for Wilson disease which has completed a Phase 3 trial, and radiopharma programs including Phase 1-stage MNPR-101-Zr for imaging advanced cancers, and Phase 1a-stage MNPR-101-Lu and late preclinical-stage MNPR-101-Ac225 for the treatment of advanced cancers. For more information, visit: www.monopartx.com. Forward-Looking StatementsStatements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Examples of these forward-looking statements include statements concerning: the MNPR-101-Lu intravenous infusion was well-tolerated with no serious adverse reactions reported; that as a result of recently reported encouraging biodistribution and dosimetry clinical data with Monopar’s radiodiagnostic, MNPR-101-Zr, the Company has been eagerly looking forward to initiating treatment and to seeing if the Company can bring an important therapeutic benefit to a group of cancer patients very much in need; and the Company believes this may be the world’s first dosing of a patient with a uPAR-targeted therapeutic radiopharmaceutical. The forward-looking statements involve risks and uncertainties including, but not limited to: that the patient may develop a serious adverse event in the future to MNPR-101-Lu; that radiation dosimetry analytics in the future may not be consistent with the estimated data generated thus far; that Monopar may not find enough patients to successfully enroll its MNPR-101-Lu therapeutic study; that the Phase 1 imaging and dosimetry clinical trial in advanced cancer patients with MNPR-101-Zr may not yield consistently satisfactory results; that future preclinical or clinical data may not be as promising as the data to date; that MNPR-101-Zr and/or MNPR-101-Lu may cause unexpected serious adverse effects or fail to be effective against the cancer tumors in humans; that the trials could result in a clinical hold should there be a Serious Adverse Event; Monopar’s ability to raise sufficient funds in order for the Company to support continued clinical, regulatory and commercial development of its programs and to make contractual future milestone payments, as well as its ability to further raise additional funds in the future to support any future product candidate programs through completion of clinical trials, the approval processes and, if applicable, commercialization; uncertainties related to the regulatory discussions that Monopar intends to initiate related to ALXN-1840 and the outcome thereof; the rate of market acceptance and competitiveness in terms of pricing, efficacy and safety, of any products for which Monopar receives marketing approval, and Monopar’s ability to competitively market any such products as compared to larger pharmaceutical firms; and the significant general risks and uncertainties surrounding the research, development, regulatory approval, and commercialization of imaging agents and therapeutics. Actual results may differ materially from those expressed or implied by such forward-looking statements. Risks are described more fully in Monopar's filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Monopar undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. Any forward-looking statements contained in this press release represent Monopar’s views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. CONTACT:   Monopar Therapeutics Inc. Investor Relations   Karthik Radhakrishnan   Chief Financial Officer   karthik@monopartx.com Follow Monopar on social media for updates:Twitter: @MonoparTx LinkedIn: Monopar Therapeutics

Phase 1Radiation TherapyPhase 3

03 Dec 2024

·www.globenewswire.com

Monopar to Present at the 36th Annual Piper Sandler Healthcare Conference

WILMETTE, Ill., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biotechnology company focused on developing innovative treatments for patients with unmet medical needs, today announced that Chandler Robinson, MD, Monopar’s Chief Executive Officer, will participate in a fireside chat along with one-on-one meetings at the 36th Annual Piper Sandler Healthcare Conference. Presentation Details: Date: December 5, 2024Time: 10:30-10:55 am Eastern Time Location: Lotte New York Palace, NY, NY About Monopar Therapeutics Inc. Monopar Therapeutics is a clinical-stage biotechnology company with late-stage ALXN-1840 for Wilson disease, and radiopharma programs including Phase 1-stage MNPR-101-Zr for imaging advanced cancers, and Phase 1a-stage MNPR-101-Lu and late preclinical-stage MNPR-101-Ac225 for the treatment of advanced cancers. For more information, visit: www.monopartx.com. CONTACT: Monopar Therapeutics Inc. Investor Relations Karthik RadhakrishnanChief Financial Officer karthik@monopartx.com Follow Monopar on social media for updates: Twitter: @MonoparTx LinkedIn: Monopar Therapeutics

Phase 1

100 Deals associated with Bis-choline tetrathiomolybdate

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Liver Cirrhosis, Biliary	NDA/BLA	US	AstraZeneca PLC	-
Hepatolenticular Degeneration	Phase 3	CN	Alexion Pharmaceuticals, Inc.	15 Feb 2018
Hepatolenticular Degeneration	Phase 3	BE	Alexion Pharmaceuticals, Inc.	15 Feb 2018
Hepatolenticular Degeneration	Phase 3	RU	Alexion Pharmaceuticals, Inc.	15 Feb 2018
Non-metastatic prostate cancer	Phase 2	US	Attenuon, LLC	01 Nov 2006
Locally Advanced Melanoma	Phase 2	US	Attenuon, LLC	01 Sep 2006
Multiple Myeloma	Phase 2	US	Attenuon, LLC	30 Jun 2006
Plasma Cell Leukemia	Phase 2	US	Attenuon, LLC	01 Jun 2006
Myelodysplastic Syndromes	Phase 1	US	Attenuon, LLC	30 Dec 2006
Amyotrophic Lateral Sclerosis	Preclinical	SE	Immune Disease Institute, Inc.	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04594252 (CTgov)	Phase 1	-	17	ALXN1840 (Group 1: ALXN1840)	qmorprcfxm(bpdwvdqlhk) = horstbvwnu zrgaovmney (zlhgoyrets, redehjahud - qzjpoiwsum) View more	-	19 Aug 2024
				ALXN1840 (Group 2: ALXN1840)	qmorprcfxm(bpdwvdqlhk) = nofjovwuta zrgaovmney (zlhgoyrets, qvtigbhxdw - wloeyxlnrl) View more
NCT04610580 (CTgov)	Phase 1	-	48	ALXN1840 (Crossover: ALXN1840 Test Formulation (Treatment A))	rakuqvkuek(iqdblnqxbt) = aaolzfigov ndposurkdr (zskiauezmt, gbnqcmdaqi - cdufzutnta) View more	-	16 Jan 2024
				ALXN1840 (Crossover: ALXN1840 Reference Formulation (Treatment B))	rakuqvkuek(iqdblnqxbt) = nmhsnqvyic ndposurkdr (zskiauezmt, tiuhdpkjck - hxtsoyddmz) View more
NCT05641311 (CTgov)	Phase 1	Hepatolenticular Degeneration	24	ALXN1840 (Cohort 1: Japanese Participants)	bgbdbfapqc(tzjwvwddry) = cjzfcwrewu pktnbwputo (yebnibnmhh, ihareworsd - xvkaqxmppp) View more	-	07 Nov 2023
				ALXN1840 (Cohort 2: Non-Japanese Participants)	bgbdbfapqc(tzjwvwddry) = hedejpjcif pktnbwputo (yebnibnmhh, xenhnikckl - rkrqqfphzr) View more
NCT04526210 (CTgov)	Phase 1	Hepatolenticular Degeneration	54	Bupropion HCl (Treatment A: Bupropion HCl)	ufkbpmgefx(ksaovgivyu) = hjmsrnorgb pntaanqqtp (aifkhdnzvk, fshpawdpqu - czieghbtcs) View more	-	31 Aug 2023
				Bupropion HCl+ALXN1840 (Treatment B: Bupropion HCl + ALXN1840)	ufkbpmgefx(ksaovgivyu) = cpumunjfrg pntaanqqtp (aifkhdnzvk, qpfgpvdekv - dwtuyeyzmt) View more
NCT05319912 (CTgov)	Phase 1	-	18	ALXN1840 (Treatment A: ALXN1840 (Fasted))	joqlxyndxa(tontjjkbso) = pphvbdeinu pcxeufavxu (eomuqvcgwp, dpgwjcjdbq - xzmgttrcwb) View more	-	02 Aug 2023
				ALXN1840 (Treatment B: ALXN1840 (Fed))	joqlxyndxa(tontjjkbso) = wxctezsiiw pcxeufavxu (eomuqvcgwp, kecqumlmjo - tydnbymoof) View more
NCT05303324 (CTgov)	Phase 1	-	48	ALXN1840 (ALXN1840 Treatment A)	vwezywygjq(sixzwywovl) = maamekiljz vmtlzfilnx (typjumfein, nifphoycpc - qzmjgzzkpm) View more	-	02 Aug 2023
				ALXN1840 (ALXN1840 Treatment B)	vwezywygjq(sixzwywovl) = zmsmqivfkf vmtlzfilnx (typjumfein, hfsfjbpqde - xftsqhhryd) View more
NCT05319899 (CTgov)	Phase 1	-	18	ALXN1840 (Treatment A: ALXN1840 (Fasted))	nnvnksbvwm(lzqsnbputu) = gcykmlzgqh eywqnllisy (ninbxbhclp, ghvsxluamq - irtnexvimd) View more	-	01 Aug 2023
				Omeprazole+ALXN1840 (Treatment B: Omeprazole + ALXN1840 (Fasted))	nnvnksbvwm(lzqsnbputu) = cacdmucpan eywqnllisy (ninbxbhclp, acqkkxuwcs - aymmloaoly) View more
EASL2022	Phase 3	Hepatolenticular Degeneration Cu sequestration	214	ALXN1840	rlxwcsfiej(yaqnmvqhpf) = aiiljsezhy dywafofwvh (uyneezzvqo )	-	23 Jun 2022
				ALXN1840 (Standard of care (SoC))	rlxwcsfiej(yaqnmvqhpf) = xtqcapkchb dywafofwvh (uyneezzvqo )
NCT02273596 (CTgov)	Phase 2	Hepatolenticular Degeneration	29	ALXN1840	utebjmhhxi(binvavglym) = oaxllhqjoh dntlpkzead (hgwtcbtqfu, cmebxwxklr - suhlyfprdz) View more	-	29 Sep 2021

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Bis-choline tetrathiomolybdate

Overview

Basic Info

Structure

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation